linjc16/ctgov huggingface dataset:
Prevention of Sacral Pressure Ulcers With Preventive Dressings

Study Overview
=================
Brief Summary
-----------------
In this study we would like to find a way to prevent sacral pressure ulcers in high-risk patients by the use of a Mepilex sacral dressing. The research question we would like to answer is the following: Is the Mepilex sacral dressing a cost-effective dressing for the prevention of grade I to grade IV pressure ulcers in the sacral region in higher-risk hospitalized patients?

Conditions
-----------------
Grade I to Grade IV Pressure Ulcers in Higher Risk Patients

Intervention / Treatment
-----------------
* Device: Mepilex® Border Sacrum dressings


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: ≥18 years Admission in one of the ten high-risk departments of the azM Suspected hospital stay of 5 days or more after admission Braden score 19 or less Exclusion Criteria: Age: <18 years Pre-existing sacral pressure ulcer Pre-existing trauma to the sacrum Patient is unable to speak Dutch Patients with an inability to give informed consent Patients who are unable to give informed consent within 24h after admission Patients who are unable to give informed consent before surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mepilex® Border Sacrum dressings<br>Mepilex® Border Sacrum dressings | Device: Mepilex® Border Sacrum dressings<br>* Mepilex® Border Sacrum dressings<br>|
| No Intervention: Standard Care<br>Standard Care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the number of patients who develop sacral pressure ulcers between the group with the Mepilex® Border Sacrum dressings (Group A) and the group without any sacral dressings (Group B). | till hospital release, max 8 weeks | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pressure ulcer, dressing, prevention, higher risk patients
Scleral Hydrops and Intralabyrinthine Schwannoma

Study Overview
=================
Brief Summary
-----------------
The symptoms of intralabyrinthine schwannomas (vertigo, deafness, instability, tinnitus) cut across the symptoms found in pressure pathologies involving the inner ear, particularly the endolymphatic hydrops. Some publications have described dilatation of the membranous labyrinth (hydrops) in the presence of intralabyrinthine tumors. It would be interesting to measure the size of the saccule (structure of the membranous labyrinth) in the presence of an intralabyrinthine schwannoma, to evaluate if some of the symptoms presented by the patients could be explained by the concomitant presence of an endolymphatic hydrops (accessible to drug therapy - Betahistine).

Official Title
-----------------
Scleral Hydrops and Intralabyrinthine Schwannoma

Conditions
-----------------
Hydrops Saccular

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Age> 18, Subject having benefited from an exploration of internal auditory canals by MRI in our service at CHU de Hautepierre between January 1, 2008 and October 1, 2017 Presence on the MRI of the internal auditory ducts, including the realization of a high resolution fluid sequence of FIESTA-C (exploitable) type, of an intralabyrinthine schwannoma, without extension to the internal auditory canal. Subject who has agreed to the use of medical data for the purposes of this research. Criteria for Non Inclusion Refusal of the patient to participate in the study Absence of high resolution fluid sequence of fast imaging employing steady state acquisition (FIESTA-C) Presence of movement artifacts interfering with the interpretation of the FIESTA-C sequence Interior surgery of the inner ear or pontocerebellar angle, without preoperative imaging Inflammatory or infectious pathology of the concomitant middle or inner ear Extension of schwannoma to the internal auditory canal Impossibility of giving the subject informed information (difficulty understanding the subject,) Subject under the protection of justice Subject under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Size of intralabyrinth saccules | To measure saccule size (membranous labyrinth structure) in patients with intralabyrinthine schwannoma on a high resolution fluid sequence (FIESTA-C) in 3T MRI | 1 hour after the realization of the MRI] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hydrops sacculaire, schwannoma intralabyrinth
Ticagrelor in Fuwai Hospital

Study Overview
=================
Brief Summary
-----------------
This is a single-arm non-interventional cohort study. This study is to describe the contemporary use of ticagrelor in a real-world setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety in patients with acute coronary syndrome in Fuwai Hospital.

Official Title
-----------------
TIFU: A Non-Interventional, Descriptive Cohort Study to Describe the Use of Ticagrelor in Patients With Acute Coronary Syndrome (TIFU: Ticagrelor in Fuwai Hospital)

Conditions
-----------------
Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≧18 years Established diagnosis of acute coronary syndrome The use of ticagrelor in hospital agree to join this clinical trial and sign informed consent Exclusion Criteria: Life-expectancy <1 year Dialysis required

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| the use of ticagrelor in hospital<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with switching between clopidogrel and ticagrelor |  | 12 months | 
| Number of participants with switching between clopidogrel and ticagrelor without a reloading dose |  | 12 months | 
| Number of Participants with discontinuation of P2Y12 receptor antagonist |  | 12 months | 
| Number of Participants with ticagrelor combined with other anticoagulants |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular Mortality, Myocardial Infarction(MI), Ischemic Stoke | composite incidence Myocardial infarction is defined and subclassified in accordance with ACC/AHA/ESC third universal definition of myocardial infarction Ischemic stroke: an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction, defined by at least one of the following: Pathological, imaging, or other objective evidence of acute, focal cerebral, spinal, or retinal ischemic injury in a defined vascular distribution Symptoms of acute cerebral, spinal, or retinal ischemic injury persisting ≧24 h, with other etiologies excluded Hemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke. | 12 months | 
| Number of bleeding event will be recorded (defined in accordance with PLATO definition) |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ticagrelor, acute coronary syndrome
Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia

Study Overview
=================
Brief Summary
-----------------
The combined use of a mosquito repellent and long lasting insecticidal nets (LLINs) by household members would result in a 40% reduction in malaria prevalence compared with households that only use LLINs.

Detailed Description
-----------------
It has been recognized that the use of malaria preventive measures in combination with LLINs could improve the effectiveness of nets in preventing the disease. This study examined the effect of a combined use of mosquito repellent (i.e., Buzz Off) and LLINs on malaria prevalence in an area of unstable and seasonal malaria transmission.

Official Title
-----------------
Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Southern Ethiopia: a Cluster-randomized Controlled Trial

Conditions
-----------------
Malaria, Mosquito Repellent, Long Lasting Insecticidal Nets

Intervention / Treatment
-----------------
* Other: Mosquito repellent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All volunteer household members Exclusion Criteria: Infants less than two months Not in the study area
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mosquito repellent and LLINs group vs. LLINs group only<br>This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group). | Other: Mosquito repellent<br>* Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Malaria parasite (P. falciparum and/or P. vivax)through microscopic detection | The objective of the study is to investigate the impact of a combined use of mosquito repellent and LLINs in reducing malaria. The primary outcome of the study is detection of malaria parasites (P. falciparum and/or P. vivax) through examination of microscopic blood slides collected from finger-pricks. |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Household ownership and utilization of LLINs | Owneship and utilization of LLINs by household members during the night before the baseline survey |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malaria, Mosquito repellent, LLINs
European Neuromuscular Monitoring Survey

Study Overview
=================
Brief Summary
-----------------
This survey aims to better define the availability of the different types of anesthesia neuromuscular monitoring devices throughout European hospitals.

Official Title
-----------------
European Neuromuscular Monitoring Survey

Conditions
-----------------
Availability of the Different Types of Anesthesia Neuromuscular Monitoring Devices Throughout European Hospitals, Health Care Utilization, Medical Device Availability, Medical Staff Availability

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active Anesthesiology department heads of European Anesthesiology departments.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|Participants will be asked to fill in an online survey that will be anonimized.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire about medical equipment and staff availability | Questionnaire about all medical equipment and staff that is available site per site and what is mainly used. | 1 year |
Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas

Study Overview
=================
Brief Summary
-----------------
This trial studies biomarker expression in tissue samples from patients with bone sarcomas. Studying biomarker in tissue samples from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer

Detailed Description
-----------------
STUDY SUBTYPE: Ancillary/Correlative OBSERVATIONAL STUDY MODEL: Case-only TIME PERSPECTIVE: Retrospective BIOSPECIMEN RETENTION: Samples without DNA BIOSPECIMEN DESCRIPTION: Tissue samples obtained from Cooperative Human Tissue Network (CHTN) STUDY POPULATION DESCRIPTION: Patients enrolled on P9754 and AOST0121 clinical trials SAMPLING METHOD: Non-probability sample PRIMARY OBJECTIVES: I. To determine if there is differential expression of tumor factor (TF) among patients with osteosarcoma. II. To determine if there is an association between overall survival and disease free survival and the extent of TF expression. III. To determine if TF expression correlates with presence of gross metastatic disease at presentation, and development of subsequent metastases. OUTLINE: Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.

Official Title
-----------------
Observational - Tissue Factor Expression in Bone Sarcomas

Conditions
-----------------
Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma

Intervention / Treatment
-----------------
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tissue samples from patients with osteosarcomas obtained from the CHTN: P9754 clinical trial for patients with non-metastatic osteosarcoma AOST0121 clinical trial for patients with metastatic or recurrent osteosarcoma

Ages Eligible for Study
-----------------
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational<br>Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry. | Other: laboratory biomarker analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of high TF expression | Estimated in the analytic population as the number of samples in the population in which such expression is noted divided by 33. An assessment of the precision of such estimates will be provided by an exact binomial confidence interval. Comparison of normalized TF expression in non-metastatic versus metastatic patients will be done using the two-sample t-test. | 1 month |
Effect of the Olive Leaf Tea Ingestion in Post-prandial Glycemic Response (OLIFTEA)

Study Overview
=================
Brief Summary
-----------------
This study tests the effect of Olive Tea Ingestion in ameliorating glycemic response after a high-glycemic meal

Detailed Description
-----------------
This study is a double-blinded, randomized, placebo-controlled clinical trial with cross-over design.

Official Title
-----------------
Effect of the Olive Leaf Tea Ingestion in Post-prandial Glycemic Response (OLIFTEA)

Conditions
-----------------
Blood Glucose

Intervention / Treatment
-----------------
* Other: Olive leaf tea
* Other: Placebo tea


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: currently taking drugs interfering with glucose regulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: Each participant will test one beverage on the first visit and the other one on the second visit. A wash-out period of two weeks will be done. Allocation of the first beverage to each participant is made by randomization.
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Olive Leaf Tea<br>Olive Leaf Tea | Other: Olive leaf tea<br>* 250 mL of Olive leaf tea and a high-glycemic breakfast<br>|
| Placebo Comparator: Placebo tea<br>Placebo tea | Other: Placebo tea<br>* 250 mL of placebo tea and a high-glycemic breakfast<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood glucose | Area under the curve | 120 minutes |
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Study Overview
=================
Brief Summary
-----------------
The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Conditions
-----------------
Anxiety Disorders

Intervention / Treatment
-----------------
* Drug: MK0777


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of General Anxiety Order Exclusion Criteria: Women who are pregnant or breast-feeding History of severe drug reaction History of severe drug withdrawal symptoms such as seizures or delirium Disease of cardiovascular system Disease of the liver, kidneys, endocrine system, metabolic system or eyes History of seizures or seizure disorder History of drug or alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0777|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Study Overview
=================
Brief Summary
-----------------
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.

Official Title
-----------------
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Conditions
-----------------
Huntington Disease

Intervention / Treatment
-----------------
* Drug: Dimebon (latrepirdine)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Successful completion of 26 weeks of blinded treatment in the HORIZON study Exclusion Criteria: Any other medical illness or unstable medical condition that may interfere with their ability to comply with study procedures and abide by study restrictions, or may interfere with the ability to interpret safety information.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dimebon (latrepirdine)<br>Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter. | Drug: Dimebon (latrepirdine)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ocular Mysathenia Gravis Generalization

Study Overview
=================
Brief Summary
-----------------
Secondary ocular myasthenia gravis (OMG) generalization represents a pejorative evolution and no validated generalization prevention strategy exists. The aim of this observational study was to determine the percentage of patients with OMG generalization and identify factors predictive of that pejorative evolution. Data from patients with OMG registered in the Fondation Hospital A. de Rothschild database between January 1990 and January 2017 were collected. Among the 183 patients registered in this database, 151 patients with available informations were analyzed.

Official Title
-----------------
Use of Nomogram for Predictions of Ocular Mysathenia Gravis Generalization

Conditions
-----------------
Ocular Myasthenia Gravis

Intervention / Treatment
-----------------
* Other: Use of nomogram for predictions of Ocular Mysathenia Gravis generalization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with OMG diagnosis and its generalization who consulted between January 1990 to January 2017 at Fondation Hospital Adolphe de Rothschild and registered in the database Exclusion Criteria: - OMG differential diagnoses
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to myasthenia gravis generalization | Kaplan-meier survival estimations, descriptive and multivariate Cox model analyses were computed (age at onset, first year anti-acetylcholine receptor antibody positivity, electromyogram decrement, steroid use). | 1 year |